Source comparison
Head-to-Head vs. Cross-Trial: The Only Fair Comparisons
This is the section that keeps the rest honest. There is no study in which Sermorelin and CJC-1295 were administered to comparable subjects and measured against each other. When a source says CJC-1295 is “stronger” or “longer-lasting” than Sermorelin, it is st
This comparison does not assign a generated winner or score.
- This is the section that keeps the rest honest. There is no study in which Sermorelin and CJC-1295 were administered to comparable subjects and measured against each other. When a source says CJC-1295 is “stronger” or “longer-lasting” than Sermorelin, it is stitching together numbers from separate trials run years apart in different people — a cross-trial inference. Cross-trial inference can motivate a hypothesis; it cannot establish superiority, because differences in population, assay, dose, and design confound any direct read.
- What can be said fairly is narrow and mechanistic: the DAC form of CJC-1295 has a longer measured half-life than Sermorelin (days vs minutes), which is a pharmacokinetic fact from its own trial — not evidence that it produces better outcomes. On the evidence axis that matters for trust, the comparison is not close: Sermorelin has controlled human trials and an approval history; CJC-1295 has early-phase data and none. The evidence-tier table makes each reported role explicit.
- Sermorelin raises GH/IGF-1 in GH-deficient children
- Multicenter human clinical trial (n=110)[4]
- Well supported for that specific population and endpoint; the basis of its historical approval
- Sermorelin improves body composition in aging adults
- One small placebo-controlled RCT, 5 months (n=19)[5]
- Modest, sex-dependent (favored men); hypothesis-level, not established therapy
- CJC-1295 (DAC) raises GH/IGF-1 in healthy adults
- Phase 1/2 dose-escalation RCT (n=66)[1]
- Real short-term pharmacodynamic effect; hypothesis-generating, program discontinued
- CJC-1295 preserves GH pulsatility
- Human clinical study, healthy men[2]
- Supported for the DAC molecule; does not imply clinical benefit
- CJC-1295 (no-DAC / mod-GRF 1-29) efficacy
- No dedicated published human trial
- Not established; DAC-version data do not transfer
- Either peptide for fat loss, muscle, or performance
- No direct trials
- Not established; experimental / off-label
- Sermorelin “beats” CJC-1295 (or vice versa)
- No head-to-head trial
- Cannot be claimed from the evidence; cross-trial only